Roche Stays Upbeat Amid Skepticism On Tiragolumab’s Chances

Confirms Trial Weighted Towards Overall Survival Endpoint

 
• By Andrew McConaghie
Roche
The leader in the TIGIT inhibitor field, Roche is banking on the SKYSCRAPER 1 study results turning positive at its next analysis • Source: Shutterstock

More from Anticancer

More from Therapeutic Category